Efavirenz
- Generic Name
- Efavirenz
- Brand Names
- Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C14H9ClF3NO2
- CAS Number
- 154598-52-4
- Unique Ingredient Identifier
- JE6H2O27P8
- Background
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
...
- Indication
For use in combination treatment of HIV infection (AIDS)
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection
- Conditions
- Interventions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2013-09-06
- Target Recruit Count
- 165
- Registration Number
- NCT00006154
- Locations
- 🇨🇦
Centre Hospitalier de la Universite de Montreal (CHUM), Montreal, Quebec, Canada
🇨🇦Centre de traitment d'immunodeficience, Montreal, Quebec, Canada
🇨🇦Viridae Clinical Sciences / University of British Columbia, Vancouver, British Columbia, Canada
Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2013-07-29
- Target Recruit Count
- 240
- Registration Number
- NCT00014937
- Locations
- 🇮🇹
Spedali Civili - Carosi, Brescia, Italy
🇺🇸Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
🇺🇸Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 730
- Registration Number
- NCT00005918
- Locations
- 🇺🇸
The CORE Ctr, Chicago, Illinois, United States
🇺🇸Univ of Texas Med Branch, Galveston, Texas, United States
Tan tock Seng Hosp
A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-02
- Target Recruit Count
- 74
- Registration Number
- NCT00001122
- Locations
- 🇺🇸
UCSD, San Diego, California, United States
🇺🇸Univ of Texas Southwestern Med Ctr, Dallas, Texas, United States
Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-03-02
- Target Recruit Count
- 288
- Registration Number
- NCT00001119
- Locations
- 🇺🇸
Seattle HIVNET, Seattle, Washington, United States
🇺🇸Univ of Washington, Seattle, Washington, United States
🇺🇸Univ of Minnesota, Minneapolis, Minnesota, United States
Changing to Nonprotease Inhibitor Treatment to Improve Side Effects
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-02-28
- Target Recruit Count
- 342
- Registration Number
- NCT00021463
- Locations
- 🇺🇸
Northwestern Univ Med School, Chicago, Illinois, United States
🇺🇸Univ of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Emory Univ, Atlanta, Georgia, United States
A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 475
- Registration Number
- NCT00000912
- Locations
- 🇺🇸
USC Univ Hosp & Ambulatory Hlth Care Ctr / USC Med Ctr, Los Angeles, California, United States
🇺🇸Emory Univ, Atlanta, Georgia, United States
🇺🇸UCLA CARE Ctr, Los Angeles, California, United States
A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2014-04-17
- Target Recruit Count
- 1710
- Registration Number
- NCT00000922
- Locations
- 🇺🇸
Louisiana Comm AIDS Rsch Prog / Tulane Univ Med, New Orleans, Louisiana, United States
🇺🇸Washington Reg AIDS Prog / Dept of Infect Dis, Washington, District of Columbia, United States
🇺🇸Harlem AIDS Treatment Grp / Harlem Hosp Ctr, New York, New York, United States
A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00013897
- Locations
- 🇺🇸
Associates in Research, Fort Myers, Florida, United States
🇺🇸The CORE Ctr, Chicago, Illinois, United States
🇺🇸Ohio State Univ Hosp, Columbus, Ohio, United States
A Study to Compare the Effectiveness of Different Anti-HIV Drug Regimens in Keeping Levels of HIV in the Blood as Low as Possible
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 150
- Registration Number
- NCT00000939
- Locations
- 🇺🇸
Santa Clara Valley Med Ctr / AIDS Community Rsch Consortium, San Jose, California, United States
🇺🇸San Mateo AIDS Program / Stanford Univ, Stanford, California, United States
🇺🇸Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.